Frank Klont is a tenure track assistant professor in the department of PharmacoTherapy, -Epidemiology & -Economics at the University of Groningen (RUG) and the department of Clinical Pharmacy and Pharmacology of the University Medical Center Groningen (UMCG). In this role, he focuses on pharmacotherapy education and advancing the personalization of pharmacotherapeutic treatments, with a particular interest in utilizing ‘omics’ techniques (e.g., genomics, metabolomics) to study drug metabolism in real-world, heterogeneous populations.

Narrative CV will follow soon.

Paula Miranda is the Director of Preclinical Translation at VectorY Therapeutics, where she leads a team dedicated to developing vectorized antibodies for neurodegenerative diseases, including ALS and Huntington’s disease. At VectorY, Dr. Miranda plays a crucial role in advancing preclinical programs, overseeing proof-of-concept, efficacy, safety studies, and biomarker discovery. With a solid background in gene therapy, she has significant experience bridging scientific research and its practical applications across both academia and industry. Prior to joining VectorY, Dr. Miranda was part of R&D teams at UniQure, contributing to the successful approval of Hemgenix, a gene therapy for Hemophilia. She completed her postdoctoral research and PhD at the Academic Medical Center in Amsterdam, focusing on gene therapy development and stem cell biology.